Patents by Inventor Raymond A. Hartman

Raymond A. Hartman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10285857
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: May 14, 2019
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Publication number: 20190022134
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 24, 2019
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman (Deceased), Sandy T. Feldman
  • Publication number: 20190008678
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 10, 2019
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman (deceased)
  • Publication number: 20190008679
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 10, 2019
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman (deceased)
  • Patent number: 10092594
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: October 9, 2018
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 10070658
    Abstract: A fish processing apparatus. The fish processing apparatus includes a cutting board, a first clamp and a second clamp. The first clamp is coupled to the cutting board. The second clamp is slidably coupled to the cutting board so that the second clamp may slide towards and away from the first clamp.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: September 11, 2018
    Inventor: George Raymond Hartman
  • Patent number: 9622911
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 18, 2017
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Publication number: 20170071978
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Application
    Filed: October 26, 2016
    Publication date: March 16, 2017
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20170065826
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 9, 2017
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Patent number: 9566301
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: February 14, 2017
    Assignee: CXL OPHTHALMICS, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Patent number: 9555111
    Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: January 31, 2017
    Assignee: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20150174161
    Abstract: Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%), or more specifically between about 0.015% to about 5%, sodium iodine or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.
    Type: Application
    Filed: March 28, 2013
    Publication date: June 25, 2015
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20150126921
    Abstract: Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.
    Type: Application
    Filed: March 27, 2013
    Publication date: May 7, 2015
    Applicant: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20150088231
    Abstract: Systems and methods of ophthalmologic or ocular phototherapy treatment are provided herein. In some embodiments, the systems and methods of ophthalmic or ocular phototherapy treatment comprise applying a treatment light beam in a predetermined wavelength or wavelength range corresponding to gold (yellow to orange), red, or at least part of both the gold and red visible light wavelength ranges to at least a portion of an eye. The treatment light beam may be applied to an entire eye. In some embodiments, the selected treatment area is irradiated with light in the selected gold and/or red wavelength range at a predetermined dose for a selected time period as a primary treatment in order to treat various eye conditions and reduce eye pain or discomfort, or help to promote eye wound healing following injury or surgery, or as a secondary treatment to augment eye treatment using light in different phototherapy treatment ranges.
    Type: Application
    Filed: March 26, 2013
    Publication date: March 26, 2015
    Applicant: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Raymond A. Hartman, Sandy T. Feldman
  • Publication number: 20140194957
    Abstract: Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.
    Type: Application
    Filed: March 12, 2014
    Publication date: July 10, 2014
    Applicant: CXL Ophthalmics, LLC
    Inventors: Roy S. Rubinfeld, Sandy T. Feldman, Kevin E. Daly, Raymond A. Hartman
  • Publication number: 20120083772
    Abstract: A system for bilateral or monocular photochemical cross-linking of corneal collagen employs selectable light in a selected wavelength band as the excitation source and riboflavin as the photosensitizer. The system has an illumination source which may have multi-spectral capability, light guides for delivery of light to the optical head for projection onto the corneal surface, selectable radiation patterns to accommodate individual corneal architecture, and red light phototherapy to limit apoptosis and accelerate healing time. Aiming beams provide alignment of the optical head to the patient cornea. A microprocessor-controlled rotary solenoid mechanical shutter provides discontinuous illumination for tissue reoxygenation, and devices and methods may be included for the in situ determination of oxygen utilization and the riboflavin content of the cornea.
    Type: Application
    Filed: February 24, 2011
    Publication date: April 5, 2012
    Applicant: CURVERIGHT LLC
    Inventors: Roy Scott Rubinfeld, Sandy T. Feldman, Raymond A. Hartman
  • Patent number: 8123113
    Abstract: This invention provides a roadside mailbox that is installed in a housing that can be wholly or partially buried in the ground. The open top of the housing is closed by a door that is attached to one of the end walls by a hinge, which allows it to be pivotally moved from a closed position where it closes the top of the housing to an open position where it is substantially vertical. The mailbox is so mounted as to be pivotally movable between a secure storage position where it is entirely within the housing and an operational position where it is in position for use. Pivotal movement of the door and the mailbox is accomplished by a mechanism driven by electric power from a battery positioned in the vault, and it is operated by an actuator that can be wireless or hard-wired. A solar panel installed on the door keeps the battery charged. The mailbox also can be laterally movable so that it extends outwardly beyond the door to facilitate depositing and retrieving mail.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: February 28, 2012
    Inventor: Alfred Raymond Hartman
  • Publication number: 20100222852
    Abstract: The invention is directed to an apparatus for decolonizing microbes from skin surfaces and body cavities, in particular the decoloniziation of MRSA from nasal cavities using UVC preferably combined with visible light. The device consists of a lightguide, dispensing tip plus accessories, and a housing with a UV source, optical filtering and light collection means, shutter and timer. An internal or external radiometer provides dosimetry information to the operator. The device has additional utility in killing microbes on skin surfaces and beneath nail beds. The lightguide itself comprises the holder for the dispensing tip for use in cavities and as a holder for surface use. The dispensing tips serve to protect decolonization subjects from cross-contamination and may act to shape the nasal cavity and the light distribution pattern of the emitted UVC and visible radiation.
    Type: Application
    Filed: February 24, 2010
    Publication date: September 2, 2010
    Inventors: David B. Vasily, Raymond A. Hartman, Alfred Intintoli
  • Patent number: 6901699
    Abstract: A starter cell for starting a plant has a first opening at the topmost portion of the cell for facilitating plant seeding and growth, a second opening at the bottommost portion of the cell for facilitating root passage for air pruning of the root, and a plurality of inward-facing ridges formed vertically along the cell walls and along any cell comers. The cell is characterized in that the ridges are strategically placed to guide developing roots to avoid twisting and balling. In some embodiment the ridges have feet to provided for stacking, for example.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: June 7, 2005
    Inventor: Gary Raymond Hartman
  • Publication number: 20040186082
    Abstract: The invention is a method for the treatment of autoimmune disease and cancer comprising the application of vitamin D precursors followed by UVA or UVB or exposure to blue light. The method can also include sequential or concurrent treatment with UVB irradiation and UVA irradiation or exposure to blue light. The invention is the vitamin D precursor compositions used in the invention.
    Type: Application
    Filed: March 20, 2003
    Publication date: September 23, 2004
    Inventor: Raymond A. Hartman